Business
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for PMX, the Company’s endotoxin removal therapy for patients with endotoxic septic shock (“ESS”). The PMA submission includes clinical, non-clinical, manufacturing and quality
About this update from Spectral Medical Inc
[{"type":"image","alt":"Spectral Medical Inc.","displaySize":"","headline":null,"caption":"Spectral Medical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":216,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NbXa8xaNSIpHSiSlXWircA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09","width":216,"height":57},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/NbXa8xaNSIpHSiSlXWircA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09","width":216,"height":57}},"lazy":false},{"type":"text","content":"TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for PMX, the Company’s endotoxin removal therapy for patients with endotoxic septic shock (“ESS”).","length":422,"tagName":"p"},{"type":"text","content":"The PMA submission includes clinical, non-clinical, manufacturing and quality system information supporting the use of PMX in adult patients with ESS identified using Spectral’s FDA-cleared Endotoxin Activity Assay (“EAA™”).","length":224,"tagName":"p"},{"type":"text","content":"The submission is supported by data from the Company’s Tigris trial, a Phase 3 follow-on study evaluating PMX in patients with ESS. As previously announced, complete results of the Tigris trial out to 90 days were published in March of this year in the journal The Lancet Respiratory Medicine and demonstrated a 95.3% posterior probability of benefit for 28-day all-cause mortality in the full adjusted Bayesian analysis, as well as a greater than 99% posterior probability of benefit at 90 days. This analysis revealed an absolute risk reduction for mortality of 10.3% at 28 days corresponding to a number needed to treat (“NNT”) to prevent one death of 9.7 and 15.5% at 90-days corresponding to a NNT of 6.5.","length":710,"tagName":"p"},{"type":"text","content":"“This PMA submission represents a defining milestone for Spectral and reflects years of focused cl...